Christos Pantelis
University of Melbourne
786 Papers
5K Citations
Christos Pantelis is an academic researcher from University of Melbourne. The author has contributed to research in topics: Schizophrenia & Psychosis. The author has an hindex of 120, co-authored 723 publications. Previous affiliations of Christos Pantelis include Royal Melbourne Hospital & University of Cambridge.
Chat about Author
Papers
Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children.
TL;DR: This study aimed to measure executive function in medicated and non-medicated children with ADHD by using a computerized battery, the Cambridge Neuropsychological Test Automated Battery (CANTAB), which is sensitive to executive function deficits in older patients with frontostriatal neurological impairments.
Novel implications of Lingo-1 and its signaling partners in schizophrenia
Francesca Fernandez-Enright,Jessica L. Andrews,Kelly A. Newell,Christos Pantelis,Xu-Feng Huang +4 more
TL;DR: This is the first time that a study has shown altered Lingo-1 signaling in the schizophrenia brain, and its novel findings may present a direct application for the use of a Linga-1 antagonist to complement current and future schizophrenia therapies.
A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study
Rothanthi Daglas,Sue M. Cotton,Kelly Allott,Murat Yücel,Craig Macneil,Melissa K. Hasty,Brendan P. Murphy,Christos Pantelis,Karen T. Hallam,Lisa Henry,Philippe Conus,Aswin Ratheesh,Linda Kader,Michael T. H. Wong,Patrick D. McGorry,Michael Berk +15 more
TL;DR: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder.
Meta-analysis reveals associations between genetic variation in the 5' and 3' regions of Neuregulin-1 and schizophrenia.
M. S. Mostaid,Serafino G. Mancuso,Chenxing Liu,Suresh Sundram,Christos Pantelis,Ian P. Everall,Chad A. Bousman +6 more
TL;DR: The results suggest genetic variation at the 5′ and 3′ ends of NRG1 are associated with schizophrenia and provide renewed justification for further investigation ofNRG1’s role in the pathophysiology of schizophrenia.
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia.
M A Di Biase,Andrew Zalesky,Graeme O'Keefe,Graeme O'Keefe,Liliana Laskaris,Bernhard T. Baune,Cynthia Shannon Weickert,James S Olver,Patrick D. McGorry,G.P. Amminger,Barnaby Nelson,Andrew M. Scott,Andrew M. Scott,Ian B. Hickie,Richard B. Banati,Federico Turkheimer,Maqsood Yaqub,Ian P. Everall,Christos Pantelis,Vanessa Cropley +19 more
TL;DR: The patient cohorts in this study do not substantiate the assumption of microglial activation in schizophrenia as a regular and defining feature, as measured by 11C-(R)-PK11195 BPND, and no correlations with regional gray matter, peripheral cytokine levels or clinical symptoms were detected.